Allogene Therapeutics Stock Gains 2.09% in a Week, Receives Bullish Score from InvestorsObserver
May 24, 2023
Trending News ☀️
Allogene Therapeutics ($NASDAQ:ALLO) Inc. (ALLO) has seen its stock surge by 2.09% in the past week, prompting many investors to ask if this is a good time to invest in the company. Analysts at InvestorsObserver have given Allogene Therapeutics Inc a Bullish sentiment score, indicating that the company has seen strong investor interest in recent time. This suggests that the company could be a great investment opportunity for those looking for gains in the stock market. Allogene Therapeutics Inc is a clinical-stage biopharmaceutical company that is focused on developing and commercializing allogeneic chimeric antigen receptor T cell (CAR T) therapies for the treatment of cancer.
The company is leveraging its deep scientific and clinical expertise to develop a pipeline of off-the-shelf CAR T therapies, which are designed to reduce the time and complexity of administering cell therapy to optimize patient outcomes. Allogene’s CAR T therapies are being studied across multiple hematological and solid tumor indications in clinical trials. With its strong focus on discovering and developing innovative treatments, the company has already seen promising results in its trials, leading to a Bullish sentiment score from InvestorsObserver.
Analysis
At GoodWhale, we provide investors the opportunity to analyze ALLOGENE THERAPEUTICS‘s financials in order to make informed decisions. According to our Risk Rating analysis, ALLOGENE THERAPEUTICS is a medium risk investment in terms of financial and business aspects. Our system detected 3 risk warnings in balance sheet, cashflow statement, and financial journal. To further investigate these risks, we offer investors the chance to register on goodwhale.com. Here you can find a comprehensive review of the company’s financials, allowing you to make an informed investment decision. We understand that investing can be a daunting process, that is why we are dedicated to helping investors make the best decisions possible. With our help, you can make an informed and confident investment decision for ALLOGENE THERAPEUTICS. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Allogene Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 0.23 | -351.49 | -150207.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Allogene Therapeutics. More…
| Operations | Investing | Financing |
| -218.92 | 241.47 | 2.87 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Allogene Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 746.87 | 154.61 | 4.06 |
Key Ratios Snapshot
Some of the financial key ratios for Allogene Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -151507.3% |
| FCF Margin | ROE | ROA |
| -95403.8% | -35.2% | -29.7% |
Peers
Allogene Therapeutics Inc is a clinical-stage biopharmaceutical company, engaged in the development of allogeneic CAR T cell therapies for the treatment of cancer. Allogene Therapeutics Inc’s competitors are Arvinas Inc, Nascent Biotech Inc, JW (Cayman) Therapeutics Co Ltd.
– Arvinas Inc ($NASDAQ:ARVN)
Arvinas Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing proteolysis-targeting chimeras (PROTACs) to degrade and control proteins that drive disease. Arvinas has a market cap of 2.29B as of 2022 and a Return on Equity of -32.37%. The company’s lead product candidate, ARV-110, is in clinical development for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Arvinas is also developing ARV-471 for the treatment of HER2-positive breast cancer and ARV-825 for the treatment of urothelial cancer.
– Nascent Biotech Inc ($OTCPK:NBIO)
Nascent Biotech Inc is a clinical-stage biopharmaceutical company with a focus on developing monoclonal antibodies to treat various cancers. The company’s market cap is 26.93M as of 2022 and its ROE is 55.87%. Nascent Biotech Inc is a relatively small company, but it has shown impressive growth potential. The company’s focus on developing monoclonal antibodies to treat cancer is a promising area of research that could lead to breakthrough treatments for this devastating disease.
– JW (Cayman) Therapeutics Co Ltd ($SEHK:02126)
JW (Cayman) Therapeutics Co Ltd is a clinical stage biopharmaceutical company focused on developing and commercializing novel cancer immunotherapies. The company’s lead product candidate, JTX-2011, is a first-in-class, off-the-shelf, multi-antigen targeted T cell therapy being evaluated in a Phase 1/2 clinical trial for the treatment of solid tumors. JW (Cayman) Therapeutics Co Ltd has a market cap of 1.32B as of 2022, a Return on Equity of -19.61%.
Summary
Allogene Therapeutics Inc. has seen a 2.09% increase in their stock in the past week. InvestorsObserver Stock Sentiment Indicator has given the stock a Bullish score, suggesting that the stock is likely to continue to rise. Investors should take this into account when making decisions on whether or not to invest in Allogene. It is also recommended to do thorough research on the company and analyze their financials before investing.
Additionally, investors should keep an eye on the company’s latest developments, news, and overall performance before making any decisions.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
